Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $33,382,800.00 in Stock

Key Points

• CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health at an average price of $50.58, totaling approximately $33.4 million, resulting in a 22.96% decrease in his ownership stake.
• Hims & Hers reported a quarterly earnings miss with an EPS of $0.17, falling short of analyst expectations of $0.18, while revenue increased by 72.6% compared to the same quarter last year.
• The company's stock currently has an average rating of "Hold" from analysts, with a target price averaging $39.83, while the stock has experienced volatility with a one-year low of $13.47 and a high of $72.98.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 660,000 shares of the business's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the transaction, the chief executive officer owned 2,214,769 shares of the company's stock, valued at approximately $112,023,016.02. The trade was a 22.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Monday, July 21st, Andrew Dudum sold 125,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $49.54, for a total transaction of $6,209,095.90.
• On Wednesday, July 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.25, for a total transaction of $2,388,583.50.
• On Wednesday, July 16th, Andrew Dudum sold 2,792 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.58, for a total transaction of $141,219.36.
• On Tuesday, June 17th, Andrew Dudum sold 65,110 shares of Hims & Hers Health stock. The stock was sold at an average price of $59.22, for a total transaction of $3,855,814.20.
• On Monday, June 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.51, for a total transaction of $2,686,146.34.
• On Monday, June 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.76, for a total transaction of $7,272,488.52.
• On Friday, May 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The stock was sold at an average price of $58.25, for a total transaction of $2,768,855.50.
• On Friday, May 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $58.40, for a total transaction of $7,482,616.80.

Hims & Hers Health Stock Down 2.5%

Shares of Hims & Hers Health stock traded down $1.19 during trading on Thursday, reaching $47.14. The company had a trading volume of 23,541,855 shares, compared to its average volume of 37,400,312. The company has a market cap of $10.55 billion, a price-to-earnings ratio of 58.92, a price-to-earnings-growth ratio of 3.06 and a beta of 2.08. The firm's fifty day moving average is $53.16 and its 200-day moving average is $45.44. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.06 EPS. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. LPL Financial LLC lifted its stake in Hims & Hers Health by 1.0% during the fourth quarter. LPL Financial LLC now owns 97,958 shares of the company's stock valued at $2,369,000 after purchasing an additional 980 shares during the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in Hims & Hers Health during the fourth quarter valued at approximately $208,000. Envestnet Asset Management Inc. lifted its stake in Hims & Hers Health by 139.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company's stock valued at $1,903,000 after purchasing an additional 45,791 shares during the last quarter. Invesco Ltd. lifted its stake in Hims & Hers Health by 613.9% during the fourth quarter. Invesco Ltd. now owns 1,277,026 shares of the company's stock valued at $30,878,000 after purchasing an additional 1,098,148 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in Hims & Hers Health by 209.3% during the fourth quarter. Legal & General Group Plc now owns 572,263 shares of the company's stock valued at $13,841,000 after purchasing an additional 387,225 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Truist Financial increased their target price on shares of Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a report on Thursday, July 17th. Wall Street Zen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $39.83.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.